Abstract: The usage of RNA interference for gene knockdown in zebrafish through expression of the small interfering RNA mediators from DNA vectors has created a lot of excitement in the research community. In this work, the ability of human cytomegalovirus immediate early promoter (CMV promoter)-driven short hairpin RNA (shRNA) expression vector to induce shRNA against vascular endothelial growth factor (VEGF) gene in zebrafish was tested, and its effects on VEGF-mediated vasculogenesis and angiogenesis were evaluated. Altogether four vectors targeting various locations of VEGF gene were constructed, and pSI-V4 was proven to be the most effective one. Microinjection of pSI-V4 into the zebrafish embryos resulted in defective vascular formation and down regulation of VEGF expression. In situ hybridization analysis indicated that silencing VEGF gene expression by pSI-V4 resulted in down regulation of neuropilin-1 (NRP1), a potent VEGF receptor. Knockdown of VEGF expression by morpholino gave the same result. This provided evidence that the VEGF-mediated angiogenesis in zebrafish was in part dependent on NRP1 expression. The results contributed to a better understanding of molecular mechanisms of cardiovascular development and provided a potential promoter for making inducible knockdown in zebrafish.
Introduction
Zebrafish is an excellent model for vertebrate embryonic development study and drug screening. It has a number of advantages compared to mice, including rapid embryonic development, transparency and the ability to examine and manipulate embryos outside of the animal. Moreover, zebrafish can take up nutrients from the yolk sac and can survive for several days without circulation, which make zebrafish a good model to study vascular development (de Jong & Zon 2005; Tanaka et al. 2008) .
Vascular endothelial growth factor (VEGF) is a key angiogenic growth factor that regulates vertebrate embryonic vascularization, adult physiology such as wound healing and reproduction as well as many human diseases (Ferrara 2004; Loureiro & D'Amore 2005) . Embryos lacking only a single VEGF allele display abnormal blood vessel development and lethality (Carmeliet et al. 1996) . The human VEGF gene is organized into eight exons, separated by seven introns. At least six VEGF isoforms including VEGF 121 , VEGF 145 , VEGF 165 , VEGF 183 , VEGF 189 , and VEGF 206 are produced through alternative splicing. The major forms secreted by most type of cells are VEGF 121 , VEGF 165 and VEGF 189 (Robinson & Stringer 2001; Tammela et al. 2005 ). VEGF knockout mice show different biological functions of VEGF isoforms. Mice expressing only VEGF 164 (human VEGF 165 ) are viable and healthy, while mice expressing only VEGF 188 (human VEGF 189 ) display impaired arteriolar development.
This study illustrates the importance of VEGF 165 as the principal effector of VEGF action (Stalmans et al. 2002) . Three VEGF receptor tyrosine kinases, VEGFR-1, VEGFR-2, VEGFR-3, and two neuropilins (NRP1, NRP2) are now known to serve as VEGF recep-1026 S. Yang et al. 
a Sequence positions were shown relative to the 5' end of the VEGF 165 mRNA (GenBank Accession No. AF016244). BamH I and Hind III restriction sites over hanged are underlined. Italic letters indicate the loop structure. Bold sequences represent mismatched bases.
tors for VEGF induced signaling (Robinson & Stringer 2001; Tammela et al. 2005) . In zebrafish, alternative splicing generates multiple VEGF-A mRNA isoforms with VEGF 121 as the dominant isoform in adult and VEGF 165 as the dominant isoform in early embryo (Liang et al. 2001; Gong et al. 2004) . Morpholino (MO) inhibition study shows that loss of VEGF function results in major blood vessel deficiencies and enlargement of the pericardium in zebrafish (Nasevicius et al. 2000 ). MO appears to be a potentially attractive method for loss-of-function study and it has been the most successful knockdown strategy in zebrafish. However, the application of the technique is limited to the first few days of embryo development, and it is quite costly and non-heritable. RNA interference (RNAi) is a powerful tool in silencing gene expression by inducing the sequence-specific degradation of complementary mRNA or by inhibiting translation via 21-22 nt small interfering RNA (siRNA). It is possible to sustain the effect of RNAi through generation of the siRNA from vector based short hairpin RNA (shRNA), and it has many advantages such as low cost and easy preparation. Moreover, the target gene expression is reduced for weeks or even months (Brummelkamp et al. 2002; Czauderna et al. 2003) eclipsing the 3-5 days typically observed with in vitro prepared siRNA. Perhaps this makes the greatest advantage of using RNAi compared with other gene knock-down strategies like MO.
Although the usage of RNAi for gene knockdown in zebrafish has created a lot of excitement in the research community, it is still in the exploring stage (Schyth 2008) . Moreover, mass study to date in zebrafish use chemically synthesized siRNA or in vitro transcribed siRNA (Dodd et al. 2004; Liu et al. 2005 ). In the vector construct, promoters of RNA polymerase III have been widely used for transcription of shRNA since RNA polymerase III is a polymerase specialized for transcribing small, high abundant non-coding RNAs (Paule & White 2000) . Xie et al. (2005) reported that fathead minnow cells transfected with mouse U6 promoter driven shRNA expression vector showed little silencing effect of target gene expression, suggesting the low transcription efficiency of mammalian RNA polymerase III promoter in fish cells. It has recently been shown that RNA polymerase II is capable of expressing functional siRNA using human cytomegalovirus immediate-early promoter (CMV promoter) (Du et al. 2006; Su et al. 2008) . In order to further evaluate the vector-based system for use in zebrafish species, we explored the CMV promoter to induce shRNA against VEGF gene. Its effect on NRP1 expression, a potent VEGF receptor, was also tested.
Material and methods

Embryo collection and microinjection
Zebrafish were cultured at 28.5
• C on a 14 h light and 10 h dark cycle. Embryos were generated and maintained according to the zebrafish book (Westerfield 1995) . RNA and plasmids were introduced into zebrafish embryos by pressure injection with about 3 nL solution to the blastodiscs of embryos at the 1-2 cell stage under a standard dissecting microscope (Leica, Wetzlar, Germany). The micropipettes were pulled from 1.0-mm glass capillaries using a PN-3 glass microelectrode puller (Narishige, Takyo, Japan). The embryos were sorted into holding groove made of 1% agarose to immobilize them for injection; 0.1% phenol red was used as trace indicator.
siRNA design and shRNA expressing vector construction The potential shRNA target sites in zebrafish were determined using the Ambion siRNA design program (Ambion, Austin, TX) and the siRNA database. We preferably chose the sites with GC% between 40% and 55%, and searched GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) to confirm the specificity of the selected sequences. Four shRNAs targeting different sequences of VEGF were prepared. The sequences and corresponding locations for the four representative shRNAs are shown in Table 1 . The forward and reverse synthetic oligonucleotides were annealed and inserted into the Hind III and BamH I sites of the linear pSilencer 4.1-CMV vector skeleton to construct shRNA expression vectors, pSI-V1, pSI-V2, pSI-V3 and pSI-V4, respectively. pSI-V4M had similar sequence to pSI-V4, but involved 4 base mismatched sequences and were used as negative control.
Morphological observation and vessel staining
The gross morphological defects of embryos were inspected under an inverted microscope (Zeiss, Jena, Germany). To assess blood vessel formation, alkaline phosphatase staining using nitro-blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3'-indolylphosphate p-toluidine salt (BCIP) was performed as described previously (Habeck et al. 2002) . Images of embryos were taken using a digital camera attached to the computer and analyzed using image acquisition software (Microscopy Documentation system 120).
RNA quantification by real-time quantitative PCR (RTqPCR)
Total RNA was isolated from embryos using TRIzol reagent (Invitrogen, Carlsbad, California) according to the manufacturer's instruction. First strand cDNA was synthesized in a 25 µL reaction using AMV reverse transcription system (Promega, Madison, Wl). SYBR Green PCR amplifications were carried out under the following condition: 95
• C for 3 min, followed by 40 cycles of 95
• C for 30 s, 58
• C for 40 s and 72
• C for 40 s. All reactions were performed in triplicate. β-Actin was used as an internal standard. Relative expression was calculated by using a modified comparative cycle threshold (CT) method, in which CT was defined as the cycle numbers at which fluorescence reached a set threshold value. The relative expression level of the experiment group to the control group was described using the equation 2 −∆∆CT , and the value standed for a 1/n-fold difference relative to the control. The sense and antisense primers for VEGF were: 5'-CCCACATACCCAAAGAAG-3' (sense); 5'-ACAGCGCATGAGAACCAC-3' (antisense). The sense and antisense primers for NRP1 were: 5'-GAAAGGACGGTTCCTGATGA-3' (sense); 5'-TTGAGT CGTGATCGTTCTGC-3' (antisense).
In situ hybridization
Sense and antisense VEGF and NRP1 probes were generated by in vitro transcription in the presence of digoxigenin-11-UTP (Roche, Mannheim, Germany). The injected embryos were fixed with 4% paraformaldehyde in PBS at 4
• C overnight and kept in methanol at −20
• C until further treatment. Embryos were rehydrated stepwise with 50%, 70%, and 100% PBT and then digested with proteinase K (10 µg/mL) for 5 to 25 min (depending on the stage and batch of enzyme). Hybridization was performed at 65 • C; 75% 0.2 × SSC/PBT for 10 min at RT; 50% 0.2 × SSC/PBT for 10 min at RT; 25% 0.2 × SSC/PBT for 10 min at RT; PBT two times for 5 min at RT), embryos were blocked for 1-4 h with PBT plus blocking reagent (5% new born calf serum). The embryos were then incubated with alkaline-phosphatase coupled anti-digoxigenin Fab-fragment (Roche, diluted 1:5000 in blocking solution) overnight at 4
• C. After washing with PBST to remove antibody, 6 times for 5 min each, embryos were immersed in staining buffer (100 mM Tris at pH 9.5, 50 mM MgCl2, 100 mM NaCl, 0.1% Tween-20) two times for 10 min each. Detection was performed in staining buffer with 4.5 µL NBT and 3.5 µL BCIP per mL added (Sigma, St. Louis, MO) (NBT, 75 mg/mL in 70% dimethylformamide; BCIP, 50 mg/mL in dimethylformamide). After 30 min to overnight reaction, samples were treated with 1 mM EDTA to stop the reaction. Images of the embryos were monitored under a stereo-microscope (Zeiss) and collected using a digital camera attached to the microscope. 
Results
Construction of VEGF shRNA vectors
Altogether four potential shRNA target sites in zebrafish were chosen. The DNA template for expressing shRNA was inserted between CMV promoter and simian virus-40 (SV40) terminator to construct shRNA vectors pSI-V1, pSI-V2, pSI-V3 and pSI-V4. Zebrafish VEGF mRNA sequences of pSI-V2, pSI-V3 and pSI-V4 were contained within the common exon of VEGF 165 and VEGF 121 , and the targeted sequence of pSI-V1 was contained within the 3'UTR of VEGF gene. All final shRNA expression constructs consisted of a CMV promoter, shRNA sense sequence, loop sequence, shRNA antisense sequence, SV40 termination sequence, and the pSilencer 4.1-CMV vector skeleton. DNA sequencing showed that the oligonucleotides inserted were the same as we designed, suggesting that the plasmids were successfully constructed. Inhibition of VEGF expression by different shRNA vectors We designed four shRNA vectors targeting different locations of VEGF to analyze the function of CMV promoter and to assess the effect of target position on gene silencing. Aliquots of 0.6 ng of four shRNA vectors were microinjected into zebrafish embryos at 1-2 cell stage and total RNA was isolated from embryos at 48 hpf (hours post fertilization). RT-qPCR analysis indicated that the expression of VEGF was down regulated to various degrees after injection of each of the four shRNA vectors (Fig. 1) . The mRNA level of pSI-V4 injected embryos was the lowest and 69 ± 1.86% of VEGF mRNA expression was blocked. pSI-V2 and pSI-V3 showed a moderate inhibitive effect, VEGF mRNA levels were decreased by 38.5 ± 1.75% and 41.6 ± 2.05%, respectively. pSI-V1 resulted in a slightly decrease but not significant alteration of VEGF mRNA expression in zebrafish (p > 0.05). We therefore chose pSI-V4 as the preferable vector to further assess the effects of CMV promoter driven vector on zebrafish vascular development. Morphological effects of pSI-V4 on zebrafish pSI-V4 was microinjected into zebrafish embryos and the morphological changes were observed under an inverted microscope. During the first day of development, no overt differences were observed between normal and injected embryos. At 48 h, however, a pericardial edema and slight reduction of body size were observed (Fig. 2C) , consistent with the enlargement of the pericardium caused by VEGF MO (Nasevicius et al. 2000) . The circulation of blood cells was either missing or slower compared with the normal embryos. Erythrocytes accumulated above the ICM (intermediate cell mass) regions and the tails in some embryos.
pSI-V4 caused vascular development defects in a dosedependent manner To observe vessels directly, alkaline phosphatase staining using NBT and BCIP was performed. The zebrafish displayed dose-dependent reduction of vascular function. In the severely affected of 1 ng pSI-V4-injected embryos, no circulating red blood cells were observed except in the yolk sac and heart. The SIVs (subintestinal veins) were completely absent (Fig. 3D ). An almost complete lack of Se (intersegmental vessels) and a severe reduction of circulation in the axial vessels were observed in embryos injected with 0.6 ng of pSI-V4 (Fig. 3H) . A less severe phenotypic class of embryos was observed in embryos injected with 0.2 ng pSI-V4. Normal patterning of axial vessels and reduced patterning of SIVs and Se were observed in about 50% injected embryos (Table 2) , consistent with the dose dependence of VEGF function in mouse embryos (Carmeliet 61 ± 8 5 7± 8 5 9± 9 5 2± 11 63 ± 9 6 8± 7 T o t a l 9 0 9 0 9 0 9 0 9 0 9 0 a Different dose of pSI-V4 were injected and control fish were injected with 1 ng control shRNA vector. The data shown were the results of three individual injection experiments. The differences between the average frequency and the individual experiment frequencies were averaged and entered into the table as standard errors. . 1996) . The SIVs were thin and the size of the area encompassed by the entire basket was decreased (Fig. 3C) . The Se were either missing or failed to form correct connections between the DA (dorsal aorta) and the PAV (parachordal vessel) (Fig. 3G) .
Influence of pSI-V4 on VEGF and NRP1 gene expression In situ hybridization was performed to further investigate the expression profile of VEGF after pSI-V4 injection. At 36 hpf, VEGF was expressed in the pharyngeal arches, brain, and anterior pronephric ducts region. Down regulation of VEGF expression in the anterior pronephric ducts and brain regions were found after injecting pSI-V4 into zebrafish zygotes (Fig. 4B) , indicating that the endogenous VEGF was knocked down to some degree. We then analyzed the expression profile of a VEGF receptor, NRP1, in the injected embryos. Decreased expression in gut endoderm and ventromedial region of the somites was observed at 24 hpf (Fig. 4D ) compared with wild-type embryos (Fig. 4C ).
Quantitative analysis of NRP1 expression by RT-qPCR after VEGF MO injection
To further confirm the effect of VEGF gene knock- down on NRP expression, we injected the VEGF MO described previously into 1-2 cell stage zebrafish embryos (Nasevicius et al. 2000) . RT-qPCR was performed to quantify the NRP1 mRNA transcript. The relative NRP1 level was reduced by 38 ± 1.75% (p < 0.01) in the experimental group. The mRNA transcripts were not significantly different between normal and pSI-V4M control group (p > 0.05; Fig. 5 ).
Discussion
VEGF, a key angiogenic growth factor, is an attractive target for anti-tumor therapy (Ferrara 2004; Loureiro & D'Amore 2005) . The functions of VEGF include regulating vertebrate embryonic vascularization, adult physiology such as wound healing and reproduction as well as many human diseases. In this report, we chose VEGF as the target gene to inspect the usage of CMV promoter in zebrafish because the phenotype could easily be observed. Furthermore, targeting VEGF with specific vector-based siRNA expression system might have therapeutic benefit due to the central role of VEGF in vascular development and tumor angiogenesis. Permanent gene suppression can be achieved by shRNAs transcribed from vector and selecting a proper expressing vector is a crucial step for the success of vector-based RNAi experiment. Many commonly used systems for expressing siRNA in cells use an RNA polymerase III promoter such as U6, H1 or 7SK (Czauderna et al. 2003; Mittal 2004 ). This approach, however, has a major drawback: inhibition cannot allow for time or tissue specific manner because the polymerase III promoter is ubiquitously expressed (Yuan et al. 2006 ). It has recently been shown that RNA polymerase II is capable of expressing high level of functional siRNA (Xia et al. 2006; Su et al. 2008) . In our present study, four 19 bp reverse repeated motifs targeting VEGF gene were synthesized and cloned into pSilencer 4.1-CMV vector, which contained a modified RNA polymerase II promoter and SV40 polyadenylation termination signal. The CMV promoter had the advantage of being highly active in a broad range of cell types (Gibbs et al. 1994) , and it does not interfere with other transcription events as might be caused by RNA polymerase III. Using RT-qPCR, blood vessel staining, and in situ hybridization, we confirmed certain suppression activity by CMV promoter-driven shRNA vector. No obvious changes were observed in mutant control vector injected embryos at both phenotypic and molecular biological level, and this indicated to some degree that the off-targeting of the shRNA construct driven by CMV promoter did not significantly affect the expression of the target gene. The system provided a potential promoter for making inducible knockdown in zebrafish.
Previous study found that knockdown of VEGF expression by MO resulted in the enlargement of pericardium, defective vasculature and abnormal blood cell pooling at the ventral tail (Nasevicius et al. 2000) . This phenotype has some similarity with our present study using shRNA to silence the expression of VEGF. However, over-expression of VEGF could also cause pericardial edema and abnormal blood cell circulation (Liang et al. 2001) . It is possible that VEGF over-expression can generate defective vasculatures by increasing the permeability of the vessels, as VEGF is a potent vascular permeability factor (Bates et al. 2002) . Hence the choice of phenotypic and molecular biological read outs were used simultaneously to estimate the effect of the vector.
Neuropilins are the second class of VEGF receptors described after the three receptor tyrosine kinases VEGFR-1, VEGR-2, and VEGFR-3. In humans, this small family includes two known members, NRP1 and NRP2. NRP1 may act as a co-receptor for VEGFR-2 (Robinson & Stringer 2001; Tammela et al. 2005) . Studies have shown that neuropilins play an important role in vascular development, as shown in a series of mouse knockout studies. NRP1 knockout mice are embryonically lethal at 12.5 to 13.5 days post copulation with abnormal axonal networks and defects in yolk sac and embryonic vascular formation (Kawasaki et al. 1999) . Study in zebrafish has shown that NRP1 regulates zebrafish angiogenesis in a VEGF-dependent pathway and knockdown of ZNRP1 reduces VEGF activity significantly. NRP1 MO-treated zebrafish showed vascular defects including short-circuited blood flow and a lack of circulation in the ISV, the DLAV (dorsal longitudinal anastomotic vessel) and the caudal vein plexus.
On the other hand, even though MO was injected at the one-cell stage, the axial vessels appeared normal. Zebrafish, treated with both NRP1 and VEGF MO at concentrations where neither MO alone had any significant effects on blood vessel circulation, exhibited a total loss of circulation throughout the trunk, the axial vessels and the ISV. This demonstrated that VEGF and NRP1 cooperated in maintaining trunk axial and ISV function (Lee et al. 2002) . Wang et al. (2007) demonstrated that NRP-1 mediated VPF/VEGF-induced endothelial cell survival in a VEGFR-2 independent way. The influence of VEGF knock down on NRP1 expression in zebrafish is uncertain now. In our present study, we observed selective down regulation of NRP1 in the VEGF gene loss of function model. This might suggest that the VEGF-mediated agiogenesis in zebrafish was dependent in part on NRP1 expression. The selective inhibition of NRP1 expression in VEGF loss of function embryos might imply in turn that VEGF could not only activate endothelial cells directly but also could contribute to stimulating angiogenesis in vivo by a mechanism that involved up-regulation of its cognate receptor expression in zebrafish. This contributed to a better understanding of molecular mechanisms of cardiovascular development and disease and widened the possibilities for better therapeutic targets. 
